Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bone Mineralization Clear all

Conditions: Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function, Vascular Calcification, Coronary Artery Calcification, Mineral and Bone Disorder (CKD-MBD), Peripheral Arterial Disease, Systemic Inflammation, Chronic Kidney Disease
Interventions: Low-dose Colchicine at 0.5mg daily, Usual Care; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 30 Years to 69 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Bone Mineral Density
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 10 Years to 12 Years · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Bone Diseases, Metabolic, Depression, Involutional, Osteoporosis
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis
Interventions: Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more

Conditions: Vitamin D Status, Glucose Tolerance, Blood Pressure, Bone Mineral Density, Hyperlipidemia
Interventions: Vitamin D; Other
Lead sponsor: Baltimore VA Medical Center; Federal
Eligibility: 45 Years to 85 Years
Enrollment: 362 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection, Alcohol Use, Bone Disease, Substance-Related Disorders
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Prostate Cancer
Interventions: dual x-ray absorptiometry; Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Renal Osteodystrophy, End Stage Renal Disease
Interventions: calcitriol, growth hormone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 1 Year to 18 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bone Density, Bone Loss, Anorexia Nervosa, Eating Disorder, Atypical Anorexia Nervosa
Interventions: Denosumab 60 MG [Prolia], Placebo Injection, Alendronate 70Mg Tab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End Stage Renal Disease, Kidney Transplantation, Bone Loss, Fractures, Vascular Calcifications
Interventions: Vitamin D3, Calcitriol, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Bone Metabolism
Interventions: testosterone cypionate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 30 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pseudoxanthoma Elasticum
Interventions: Non Interventional; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hyperparathyroidism, Secondary
Interventions: Etelcalcetide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 45
States / cities: Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more

Conditions: Osteoporosis
Interventions: Behavioral modification - nutrition education; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 7 Years to 10 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uterine Fibroid, Endometriosis
Interventions: Not listed
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 660 participants
Timeline: 2018 – 2020
U.S. locations: 37
States / cities: Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more

Conditions: HIV, Osteoporosis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoporosis
Interventions: BONISTEIN(R) bone blend, Placebo; Dietary Supplement
Lead sponsor: dsm-firmenich Switzerland AG; Industry
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Vitamin D Deficiency
Interventions: High Dose Vitamin D3, Low Dose Vitamin D3, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 75 Years · Female only
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Neoplasms
Interventions: Vitamin D, Calcium carbonate, Vitamin D, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate/Vilanterol, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Jasper, Alabama • Phoenix, Arizona • Fort Lauderdale, Florida + 14 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Creighton University; Other
Eligibility: 5 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bone Mineral Density, Childhood Cancer Survivors
Interventions: Dual energy x-ray absorptiometry (DXA), Peripheral quantitative computed tomography (pQCT); Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 8 Years to 20 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV Infection, Bone Mass
Interventions: cholecalciferol plus calcium carbonate; Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 16 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Hip
Interventions: OMNI Apex Modular™ Hip Device, OMNI Apex ARC™ Hip Device; Device
Lead sponsor: Spokane Joint Replacement Center; Other
Eligibility: 20 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Spokane, Washington

Search by objective public record fields.

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial

The Role of Impact Activity in Peripubertal Bone Accrual

Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

Vitamin D Retrospective Study and Role With Disease

Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort

Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

Bone Mass and Strength After Kidney Transplantation

The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa

Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Building Better Bones in Children

Bone Mineral Density in Women With Uterine Fibroids or Endometriosis

Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)

Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health

Treatment of Vitamin D Insufficiency

High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Type 1 Diabetes Mellitus Bone Mineral Density in Childhood and Adolescence

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

The Effect of Vitamin D and Calcium on Bone in Pediatric HIV

Femoral Remodeling Following Total Hip Arthroplasty With OMNI Apex Modular™ and OMNI Apex ARC™ Stem Compared to Competitive Designs